Please login to the form below

Hanover Health launches the Mackay Programme

New programme for communicators looking to breakthrough in their careers.

Hanover Health has today launched The Mackay Programme to offer experienced professionals the opportunity to switch careers by joining an award-winning healthcare communications consultancy that helps to change the lives of millions for the better.

The programme, open to non-healthcare agency professionals and experienced communicators working in the wider healthcare sector, will provide comprehensive training and development to help propel successful candidates into a global healthcare communications career.

The selected candidates will join the Hanover Health team, who provide smart thinking, refreshing storytelling and breakthrough solutions to a wide range of global clients including: pharmaceutical and medical technology companies, healthcare service providers, charities, professional and public-sector bodies.

The programme will include:

· Fundamental training on our company, our services, our healthcare offer and how the business is run

· Industry-recognised training opportunities and participation in our Hanover Academy training programme

· Investment and budget to spend on CPD or professional qualifications to further career development

· Attendance at industry conferences and events

· The ability to draw on our network of experts in the sector (the Hanover Group is part of AVENIR GLOBAL, a global network of comms and public affairs consultancies)

· Opportunities to work with colleagues in our Brussels, Dublin and Middle East offices

· Immersion within an entrepreneurial environment

· Hanover Group benefits and additional perks

Successful candidates will be placed at levels ranging from Consultant up to Associate Director.

This opportunity is suited to those with a passion for communications and a drive to join a fast-paced, breakthrough industry.

Applicants must be able to demonstrate strong communications skills and an interest in the sector but no prior experience in healthcare is necessary. Applications close: Friday 10th April 2020. Shortlisted candidates will be invited to interview at the Hanover office in London.

The Mackay programme is dedicated to one of Hanover’s founders, Gregor Mackay, who died in 2005 eight weeks after being diagnosed with a rare form of cancer. Mackay personified an “uncommon sense” approach and took particular interest in the development of people and teams.

Andrew Harrison, Managing Director of Hanover Health, said:

“At Hanover Health, we recognise that the best innovation and creative problem-solving requires diverse thinking.

This is why we’re looking for the brightest minds across communications, public affairs and healthcare, to help bring fresh thinking, bold ideas and broad experience into the industry. The sector is constantly evolving, and this opportunity offers a different cohort of talent the chance to be part of this change, working with clients who are on the cusp of the latest research and technology to improve lives for the better.

It is only fitting to name it after Gregor Mackay, a man who personified the breakthrough approach, and who recognised the transformational power of great communications.”

For more information and to apply please visit www.hanovercomms.com or contact recruitment@hanovercomms.com.

-ends-

NOTES TO EDITORS

  1. Hanover Health’s team provides product and corporate communications, market access, policy and public affairs at an international and local level from its offices in London, Brussels, Dublin, Dubai and Abu Dhabi. Hanover Health is part of the wider Hanover Group. Hanover Group is part of the AVENIR GLOBAL group of companies. More information can be found at www.hanovercomms.com.

2. Hanover Health works with over half of the world’s top 20 pharmaceutical companies, as well as health technology businesses, trade associations, charities and healthcare providers. The fast-growing practice has been an important part of the Hanover Group’s overall expansion – a 25% average annual growth rate for the last five years.

3. Hanover Health won three prestigious industry awards in 2019: PharmaTimes International Team of the Year, EMEA Sabre Medical Technology and PRWeek Awards: Issues and Reputation Management.

4. Hanover Health is chaired by Sarah Matthew, co-founder of Virgo Health and one of the most influential figures in healthcare communications.

11th February 2020

Share

Tags

Company Details

Hanover Communications

+44 (0)20 7400 4480

Contact Website

Address:
Riverside House
Southwark Bridge House
London
SE1 9HA
United Kingdom

Latest content on this profile

What do NHS changes and the Life Sciences Vision mean for medicines?
With the publication of the new Life Sciences Vision, a new NHS Bill, and new Health Secretary and NHS England Chief Executive, there are many fresh additions to add to the blur of change in the NHS. But what do they mean for medicines? In his latest blog, Hanover Health’s Andrew Harrison argues that there is a need for a renewed value story for medicines in the NHS, one which articulates their contribution to the prevention agenda and how they can relieve the burden of care on the health system.
Hanover Communications
Addressing the Gendered Health Data Gap
The Women’s Health Strategy for England presents an opportunity to ensure that gendered inequalities in health data are recognised and addressed. Caroline Cirado Perez’s ‘Invisible Women’ highlights how women are missing from data sets leading to health interventions and technologies designed for men as the default. For example, women are 50% more likely to be misdiagnosed following a heart attack because participation in clinical trials is generally skewed towards males. In her latest blog, Hanover Health’s Emma Gorton outlines why data should form a key part of the Women’s Health Strategy to help address inequalities in outcomes for women.
Hanover Communications
Greener healthcare - a shared challenge
At six months out from the COP26 UN climate summit in November, political leaders are focusing on industry to help cut emissions. In 2019 the NHS equated to ~5% of total UK carbon footprint, and it is now targeting 2045 net zero for itself and its wider footprint. The search for healthcare suppliers that meet these commitments by the end of the decade is on, and the time to act is now. In the pharmaceutical sector manufacturing sustainable plastic, hydrogen power, or green steel are all being debated – and healthcare companies will need cross-sector support in finding futureproofed solutions. In her latest blog, Hanover Health’s Alison Woodhouse considers the steps and collaboration that will be required in order for the NHS, and UK government, to meet their ambitious net zero targets.
Hanover Communications
Why it’s in everyone’s interest the Women’s Health Strategy for England succeeds
Timed to coincide with International Women’s Day, the Government’s Women’s Health Strategy for England landed at a moment of national contemplation about women’s place in society more generally, following the murder of Sarah Everard. In her latest blog, Hanover Health’s Jennifer Blainey breaks down the strategy and considers what needs to happen for it to succeed.
Hanover Communications
COVID-19 has changed the way we must talk about treatment for rare diseases
The turbulence of the last year has brought into sharp focus the difficult choices to be made when it comes to healthcare prioritisation. There is now more of a reluctant acceptance that there will always be someone or something that will miss out so the ‘unjust’ emotional argument won’t resonate in the same way anymore. In her latest blog, Hanover Health’s Emma Gorton considers why in the wake of Covid-19, communicators must change their narrative around the treatment of rare diseases.
Hanover Communications
What does the COVID-19 vaccine mean for the future of R&D?
Amid a pandemic, time is a luxury the world cannot afford. The last 12 months have contradicted what we once thought about the speed of progressing scientific research. Here Shannon Lacombe explores the factors that have contributed to the unprecedented speed of vaccine development from early-stage research to mass public rollout. She also looks at what precedent this has set for the future of research and development timelines and the assumptions and status quo that will now be challenged as a result.
Hanover Communications